BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gantner P, Cotte L, Allavena C, Bani-Sadr F, Huleux T, Duvivier C, Valantin MA, Jacomet C, Joly V, Chéret A, Pugliese P, Delobel P, Cabié A, Rey D; Dat’AIDS Study Group. Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection. PLoS One 2019;14:e0215464. [PMID: 30998789 DOI: 10.1371/journal.pone.0215464] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Yoshikawa S, Yoshio S, Yoshida Y, Tsutsui Y, Kawai H, Yamazoe T, Mori T, Osawa Y, Sugiyama M, Iwamoto M, Watashi K, Kawaguchi T, Akita T, Tanaka J, Kikuchi Y, Mizokami M, Oka S, Kanto T, Gatanaga H. Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus/Human Immunodeficiency Virus-1 Coinfected Patients. J Infect Dis 2021;223:2080-9. [PMID: 33073291 DOI: 10.1093/infdis/jiaa662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Jain MK, Vigil KJ, Parisot P, Go G, Vu T, Li X, Hansen L, Taylor BS. Incidence and Predictors of Hepatitis B Surface Antigen Clearance in HIV Patients: A Retrospective Multisite Study. Open Forum Infect Dis 2021;8:ofab116. [PMID: 34337091 DOI: 10.1093/ofid/ofab116] [Reference Citation Analysis]
3 Audsley J, Sasadeusz J. Challenges and opportunities for hepatitis B cure in the setting of HIV--hepatitis B virus co-infection. Curr Opin HIV AIDS 2020;15:193-9. [PMID: 32141889 DOI: 10.1097/COH.0000000000000624] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hawkins C, Kang M, Bhattacharya D, Cloherty G, Kuhns M, Matining R, Thio C, Samaneka W, Chinula L, Mulinda N, Badal-Faesen S, Sugandhavesa P, Lama J, Gaseitsiwe S, Holzmayer V, Anderson M, Murphy R, Peters M. Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy. AIDS 2022;36:975-84. [PMID: 35165216 DOI: 10.1097/QAD.0000000000003193] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Boyd A, Dezanet LNC, Lacombe K. Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review. Viruses 2021;13:1341. [PMID: 34372547 DOI: 10.3390/v13071341] [Reference Citation Analysis]
6 van Bremen K, Hoffmann C, Mauss S, Lutz T, Ingiliz P, Spinner CD, Scholten S, Schwarze-Zander C, Berger F, Breitschwerdt S, Schneeweiss S, Busch F, Wasmuth JC, Fätkenheuer G, Lehmann C, Rockstroh JK, Boesecke C. Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection. Liver Int 2020;40:2978-81. [PMID: 33012099 DOI: 10.1111/liv.14684] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wang W, Smith N, Makarov E, Sun Y, Gebhart CL, Ganesan M, Osna NA, Gendelman HE, Edagwa BJ, Poluektova LY. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine 2020;28:102185. [PMID: 32217146 DOI: 10.1016/j.nano.2020.102185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Guaraldi G, Milic J, Marcotullio S, Mussini C. A patient-centred approach to deprescribing antiretroviral therapy in people living with HIV. J Antimicrob Chemother 2020;75:3425-32. [PMID: 32747939 DOI: 10.1093/jac/dkaa329] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Revill PA, Lewin SR. Editorial: Strategies and barriers for hepatitis B cure: implications for HIV. Curr Opin HIV AIDS 2020;15:151-6. [PMID: 32229770 DOI: 10.1097/COH.0000000000000620] [Reference Citation Analysis]